In September 2025, the strategic alternatives review I had been quarterbacking at Y-mAbs Therapeutics (NASDAQ: YMAB) closed in a $412 million all-cash tender offer to SERB Pharmaceuticals. Three years earlier, Aerie Pharmaceuticals (NASDAQ: AERI), where I served as Chief Legal Officer, closed its sale to Alcon at $930 million total consideration.
Both transactions shared something important: by the time the merger agreement was signed, the legal department had already done the hard work. Not the deal documents. The eighteen months before them.
The deal documents are a six-week sprint with a banker, a buyer, and twelve outside lawyers in a data room. They are not where most sell-side legal value is created. The value is created — or, more often, destroyed — in the eighteen months before that sprint begins.
This is Part 1 of a three-part series for the General Counsel, Chief Legal Officer, or Chief Compliance Officer of a public or PE-backed commercial-stage pharmaceutical or biotechnology company whose board is somewhere between “thinking about it” and “we’ve engaged a banker.” If that’s you, here is the field guide.
1. The diligence room is being built right now, whether you are building it or not.
Every contract you sign in the eighteen months before a deal becomes part of someone’s diligence checklist. Every regulatory letter, every termination, every settlement, every license amendment. The buyer’s law firm is going to ask you for all of it, organized, on a timeline you do not control.
The single most expensive mistake I have seen made — and made myself, early on in my career, is treating the diligence room as a project that begins when the buyer signs the NDA. By then you are organizing eighteen months of inconsistent record-keeping under time pressure, watching your team paper over gaps the buyer will eventually find anyway.
The corrective practice: build the diligence room as a live, always-current artifact, eighteen months ahead. Folder structure, naming conventions, executed-copy discipline. When the banker arrives, you hand over a populated, indexed data room in 72 hours, not 72 days.
At Y-mAbs we maintained, throughout the strategic alternatives review, a separate “diligence-ready” version of the contracts repository — fully executed copies, side letters and amendments collated. When SERB’s counsel arrived, we granted full access in the first week. The negotiation tempo that established was worth, conservatively, low single-digit percentage points of deal value in preserved leverage.
2. Litigation cleanup is a price-discovery exercise.
Every open litigation matter you carry into a sale process is a price-discovery exercise for the buyer. Buyer’s diligence counsel will value each matter at the high end of plausible exposure plus a risk premium for the unknown, and either demand an indemnity, an escrow holdback, or a price reduction. Often all three.
The math is brutal: a single matter with a $1 million reserve can drive a $3–5 million escrow demand. Two matters can drive a $10 million holdback. The buyer is not being unreasonable — they are simply pricing in uncertainty about which you have asymmetric information.
The corrective practice: in the eighteen months before any anticipated sale, triage the litigation portfolio aggressively. Categorize each matter as (a) settle now within insurance ranges, (b) accelerate to judgment, or (c) carry into the deal with full disclosure and an offset against the indemnity cap. Most matters in most pharma portfolios fall into bucket (a) and were never going to settle for less than they will today.
At Y-mAbs, in the months before the strategic alternatives review concluded, our Legal team settled six open matters within insurance guidance ranges. None had been individually material to operations, but collectively they would have driven a meaningful escrow demand. Resolving them transferred the entire reserve dollar to the seller’s side of the closing table.
A practitioner’s tip: if your carrier resists, escalate at the carrier-relationship level, not the matter level. Carriers are far more accommodating when the request is framed as “we are closing out a multi-year program and want to settle these clean” than when it is framed as “we want to settle this specific matter.”
3. The capital structure is part of the deal.
The buyer is not just buying your product, your pipeline, and your team. They are buying a capital structure. ATM facilities, convertible notes, warrant overhangs, anti-dilution provisions, vesting accelerations, registration rights — each was a small problem at the time it was signed, and each becomes a deal-modeling input the buyer will run through their own discount.
The corrective practice: produce, eighteen months ahead, a complete capital-structure brief. Every outstanding instrument, every contingent claim on shares, every change-of-control provision. Then, where the instruments allow, simplify. Buy in cheap warrants. Renegotiate registration rights. Pre-clear amendments to the ATM facility so it can be terminated promptly post-signing.
The strategic alternatives review at Y-mAbs benefited from this discipline. The ATM facility was structured and filed in a way that allowed the board to draw on it for capital flexibility during the review without complicating the eventual tender offer mechanics. The capital structure stayed clean through to the Schedule 14D-9 filing.
4. Carve-out optionality is created on the org chart, not in the merger agreement.
If your company has two distinct businesses or product platforms — and most commercial-stage biotechs do, in some form — the buyer pool for a whole-company sale and the buyer pool for a carve-out are different sets of bidders willing to pay different prices.
Carve-out optionality is one of the highest-value strategic levers available to a selling board. But it can only be exercised if the operating segmentation is real. Shared sales force, shared corporate functions, intertwined IP, and consolidated cost centers all make carve-outs prohibitively expensive to execute.
The corrective practice: if a sale is even on the medium-term horizon, push operations toward genuine segmentation. Separate P&L visibility. Clear IP allocation. Defined cost-center boundaries. A board that can credibly entertain “we can sell the whole thing, or we can sell just the commercial product, or we can sell just the platform” has materially more leverage than a board that can only entertain one of those alternatives.
At Y-mAbs, the operating restructuring gave the board exactly this optionality during the strategic alternatives review. The bidders for the commercial product business were not the same set as the bidders for the radiopharma platform. The board’s leverage in the eventual whole-company sale was, in part, an artifact of having those carve-out alternatives credibly on the table.
What to do this week
If you are the seat GC of a company that may run a strategic alternatives review in the next 12–24 months, three concrete actions for this week:
— Pull every signed contract from the last 18 months into one folder with consistent naming.
— Walk through your litigation reserves with your CFO and identify the three matters most worth resolving in the next two quarters.
— Ask your CFO for the current capital-structure waterfall and identify the three instruments most worth simplifying.
These are not glamorous tasks. They are not the work that wins deal mentions in the Wall Street Journal. They are the work that makes those deal mentions possible.
In Part 2 of this series — next week — I will walk through the strategic alternatives review itself: the trigger events, the transaction committee setup, the banker mandate, the “process vs. negotiated” decision, and what fiduciary out actually means in practice.
If you are reading this because you have a sale process coming and you do not have a GC who has done this before, LaRocca Advisory Services provides fractional CLO engagements specifically for the 12–24 month pre-sale window. Reply to this article and we will set up a 30-minute call.
— John
Know a GC, CLO, or finance leader who’d find this useful? Forward it — genuinely, that’s how The GC Playbook grows.
And if your team has a raise, sale, or audit on the horizon, I take on a few diligence & compliance readiness reviews a year. Just reply to this email.
John (john@laroccaadvisory.com)


